Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Next Previous
Search
Trial Profile

A Phase I/II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azeliragon (Primary) ; Dexamethasone; Dexamethasone; Methylprednisolone; Methylprednisolone
  • Indications Brain metastases; Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADORATION

    • Most Recent Events

    • 04 Jun 2024 Study design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 28 May 2024 According to a Cantex Pharmaceuticals media release, the company has announced that the data of this trial will be featured in abstracts at this years 2024 ASCO Annual Meeting to be held in Chicago.
    • 28 Aug 2023 According to a Cantex Pharmaceuticals media release, company announced initiation of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top